The long-awaited confirmation of the efficacy of the COVID-19 vaccine in cancer patients has arrived and will be disseminated to an audience worldwide at the European Society for Medical Oncology’s annual meeting, a major specialist in oncology. New studies show that today cancer patients experience adequate protection against vaccination without experiencing more side effects than the general population, as many studies supporting similar conclusions have not yet been presented (tomorrow). It was revealed to show an immune response. Indirect evidence suggests that a third “booster” shot may further increase the level of protection for this patient population.
NS Patience People with cancer were excluded from Clinical trials Whether the vaccine is safe in this vulnerable population and for individuals whose immune system may be weakened by various anti-cancers, which was carried out to support the development and licensing of the vaccine. The question of whether to provide adequate protection against severe forms of COVID-19 has remained open until now.
George Pentheroudakis, Chief Medical Officer at ESMO, said: “The fact that we received over 90 summaries and excellent data on this topic underscores that this was the right thing to do.”
Protected cancer patients regardless of current tumor treatment
To investigate the potential impact of chemotherapy and immunotherapy on the protection provided by vaccination against COVID-19, the VOICE study (1) found 791 patients from multiple Dutch hospitals in cancer-free individuals. , Enrolled in four different research groups, including patients treated for cancer. Patients treated with immunotherapy, chemotherapy, and finally with a combination of chemotherapy and immunotherapy. Measure the response of Moderna to a double-dose mRNA-1273 vaccine. Twenty-eight days after the second dose, 84% of cancer patients receiving chemotherapy, 89% of patients receiving chemotherapy alone, and 93% of patients receiving only immunotherapy have the virus in their blood. The appropriate level of antibody against was found. ..
According to Dr. Antonio Passaro, ESMO Press Officer, a lung cancer expert at the European Society for Medical Oncology in Milan, Italy, these results show cancer-free individuals: “the entire study population, regardless of the type of anticancer treatment. The high efficacy rate of the vaccine observed in the patient constitutes a powerful and reassuring message for patients and their doctors, “he said.
Passaro further emphasized the importance of ensuring that cancer patients receive a complete double dose to develop sufficient protective antibodies against the virus. After the first injection, a good response was achieved. This is half the group of individuals without cancer.
This observation was reproduced in a study (2) on the effects of Pfizer–BioNTech in 232 cancer patients and 261 control subjects in Israel. At the first dose, this percentage increased to 86% after the second dose, compared to 84% in the control group. To further demonstrate the efficacy of the vaccine, only two cases of COVID-19 were reported during the study, both of which occurred in patients who did not receive a second injection.
Booster Shots May Increase Effectiveness in More Patients
Data from the CAPTURE study (3) published today show that of 585 cancer patients who received two doses of Tozina melan or AstraZeneca’s COVID-19 vaccine in the United Kingdom, 31% of those who were previously infected with COVID-19. It further shows that it was higher. Levels of virus-neutralizing antibodies, including those against mutants such as Delta, where vaccination loses some of its effectiveness. This is individually supported by a study (4) showing that the antibody response to vaccination was significantly enhanced even after the first dose of cancer patients who recovered from COVID-19.
Dr. Luis Castello Blanco, a medical oncologist in the ESMO Department of Science and Medical Sciences, an expert unrelated to research, commented: Cancer patients need improved protection because it suggests that the immune system responds to extra stimuli. ”
Research just published in New England Journal of Medicine (5) indicates that five months after completing the vaccination cycle, increased vaccination of people over the age of 60 reduced the incidence of COVID-19 and serious illness.
More data is needed to better understand who should consider boosting these vaccinations and when, but in general, prioritizing all patients with weakened immune system, including cancer patients, is a good idea. It makes sense.
“It is important to continuously reassess the efficacy of the vaccine as new variants of SARS-CoV-2 emerge in the future,” continued Castello-Branco, specializing in a subgroup of such patients. He emphasized the need to provide consideration and additional safeguards. A CAPTURE study found that more than two-thirds (69%) of people suffering from blood cancer have not developed any neutralizing antibodies against the currently predominant delta mutants after vaccination. ..
Vaccination against COVID-19 is safe for cancer patients
According to Castelo-Branco, anti-COVID vaccination is safe for both cancer and cancer patients, as these and other results presented at ESMO Congress 2021 have not reported any new adverse events. It provides definitive proof that it is. General population. This has been particularly demonstrated in a subgroup analysis (6) of 3,813 participants with a history of past or active cancer in a phase III randomized controlled trial of Tojinameran, the most common side effect of vaccination. Showed that they were the same-injection site pain, malaise, fever, chills, headache, myalgia-overwhelmingly mild and occurring as often as the entire study population (44,047 participants) bottom.
“This study excluded people with immune function who suppress anticancer treatments such as chemotherapy, but a significant proportion of cancer patients, combined with the large number of supplementary data presented, of COVID. It contributes to a comprehensive and positive picture. 19 The efficacy and safety of vaccines is a good reason for the oncological community around the world to be pleased, “says Castello-Branco.
ESMO President Solangele Peters said: “Since the outbreak of the pandemic began, ESMO has made it a top priority to ensure special care for patients. COVID-19 vaccination for cancer patients. Rich and valuable regarding the use of anti-COVID vaccines in patients. With the data published at ESMO 2021, the ESMO promise of “Good Science. Better Medicine. Best Practice” is regained.When cancer It provides hands-on guidance to the medical community, whether oncologists or other professionals, and enables them to communicate their decisions with the highest levels of health policymaking. ”
ESMO Conference: www.esmo.org/meetings/esmo-congress-2021?hit=ehp
1 Summary LBA8 “Vaccination of SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemotherapy for solid tumors” is available on Monday, September 20, 15: 05-16: 35 (CEST). ) Presented by Sjoukje Oosting at Presidential Symposium 3. Channel 1. Annual Tumor Report, Volume 32, 2021 Supplement 5
2 Summary 1559O “Efficacy and Toxicity of BNT162b2 Vaccine in Patients with Cancer” by Ithai Waldhorn during the proposed treatise session “SARS-CoV-2 and Cancer” on Tuesday, September 21, 13: 30-14: 50 (CEST). Will be announced. Channel 5. Annual Tumor Report, Volume 32, 2021 Supplement 5
3 Summary 1557O “Adaptive Immunity to SARS-CoV-2 Infection and Vaccination in Cancer Patients: CAPTURE Study” was published during Presidential Symposium 3 on Channel 1 on Monday, September 20, 15: 05-16: 35 (CEST). Announced by Scott Shepherd. .. Annual Tumor Report, Volume 32, 2021 Supplement 5
4 Summary 1563MO “CoVigi Phase IV Multicenter Clinical Trial to Evaluate COVID-19 Vaccination Adverse Events and Immune Response Dynamics in Cancer Patients: First Results on Antibodies and Cell-mediated Immunity” by Radka Obermannova during a mini-oral session Will be announced. Cancer on Channel 2 on Tuesday, September 21st, 16: 20-17: 20 (CEST). Annual Tumor Report, Volume 32, 2021 Supplement 5
5 Yinon M. Bar-On et al, Protection of BNT162b2 Vaccine Booster Against Covid-19 in Israel, New England Journal of Medicine (2021). DOI: 10.1056 / NEJMoa2114255
6 Summary 1558O “COVID-19 Vaccine in Cancer Participants (ptcpts): Efficacy / Safety Subgroup Analysis from Global Phase III Randomized Trials of BNT162b2 (Tojinameran) mRNA” Presented by Stephen J. Thomas in between the session “SARS-CoV-2 and Cancer” on Channel 5 on Tuesday, September 21st, 13: 30-14: 50 (CEST). Annual Tumor Report, Volume 32, 2021 Supplement 5
European Society for Medical Oncology
Quote: Evidence is as follows: COVID vaccine was obtained from https://medicalxpress.com/news/2021-09-evidence-covid-vaccines-patients-cancer.html on September 20, 2021. Protects (September 20, 2021)
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.
COVID vaccine protects cancer patients
Source link COVID vaccine protects cancer patients